


MELANOMA IN UNUSUAL SITES II:
**DIAGNOSIS AND TREATMENT
OF SINONASAL MELANOMA**

Stephanie Flukes FRACS (Oto-HNS)

Fiona Stanley Hospital & West Perth ENT

BACKGROUND

- 21% population have melanocytes in sinonasal mucosa
- Risk factors for development sinonasal mm unknown
- Rare & aggressive malignancy
 - <1% all melanomas
 - 4% of sinonasal malignancies
 - Incidence 0.5 per 1,000,000 per year
- Different disease than cutaneous melanoma



EPIDEMIOLOGY

- >65 yrs (oral cavity mm slightly younger)
- M=F
- No racial differences
- No geographical differences



CLINICAL PRESENTATION



- Unilateral nasal symptoms
 - Obstruction (79%)
 - Recurrent epistaxis (70%)
 - Pain, pressure, or paraesthesia (10%)
 - Involvement of adjacent structures
 - Palatal, sublabial, or facial mass
 - Visual changes
 - Headache
 - **Unknown primary neck disease (10-20%)**
-

CLINICAL PRESENTATION

- Nasal cavity > maxillary > ethmoid > oral
- May extend into adjacent areas
- 30-40% amelanotic

WORKUP

- Imaging
 - CT sinuses (+C)
 - MRI sinuses & brain
 - FDG-PET scan
- Biopsy
 - Difficult histology – “small round blue cell tumours”
 - BRAF mutations uncommon (<10%)





MANAGEMENT

- Surgery
 - Local control
 - En bloc Vs endoscopic
 - Margins ???
 - Adjuvant radiotherapy
-

Are Our Patients Doing Better? A Single Institution Experience of an Evolving Management Paradigm for Sinonasal Mucosal Melanoma

[Stephanie Flukes](#)¹, [Shivangi Lohia](#)¹, [Christopher A Barker](#)², [Jennifer R Cracchiolo](#)¹, [Ian Ganly](#)¹, [Snehal G Patel](#)¹,
[Benjamin R Roman](#)¹, [Jatin P Shah](#)¹, [Alexander N Shoushtari](#)³, [Viviane Tabar](#)¹, [Marc A Cohen](#)¹




MANAGEMENT (NON-SURGICAL)

- Primary radiotherapy
 - Less morbidity, worse survival (~15% 5y OS)
 - Reserved for unresectable disease or poor surgical candidates
 - Good palliative option
 - Systemic therapy
 - CT limited role
 - IO used but poor response
 - Ongoing interest in targeted therapies
-

PROGNOSIS

- Av. Survival 18-24mo
- 5 yrs survival ~25%
- High local recurrence rate
(*highly morbid*)
- Frequent distant mets
(*less morbid*)



SUMMARY

- Beware unilateral nasal symptoms in the elderly patient
 - Unknown primary melanoma in the neck → consider sinuses & oral cavity
 - Prognosis is poor and goal is reducing morbidity
 - Watch for emerging targeted therapies
-

QUESTIONS?

